Status:
TERMINATED
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
Lead Sponsor:
Echosense Ltd.
Conditions:
Systemic Sclerosis
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e. the transthoracic parametric Doppler (TP...
Eligibility Criteria
Inclusion
- Able and willing to give signed informed consent prior to enrollment
- Male or female, ≥ 18 years of age
- Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥ 9.
- Patients with RHC data available from measurement within 3 weeks prior to TPD assessment
- No change in or initiation of PAH specific therapy between the last RHC and TPD
Exclusion
- People unable or unwilling to give informed consent.
- PCWP or LVEDP \> 15 mmHg
- Any PH etiology outside Group 1 (Dana Point, 2008)
- Pregnant women
- Patients having severe chest wall deformity
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT02243111
Start Date
September 1 2014
End Date
December 1 2015
Last Update
January 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Reumatology department, Rabin medical center
Petah Tikva, Israel, 49100